Body mass index and breast cancer risk according to postmenopausal estrogen-progestin use and hormone receptor status

Epidemiologic Reviews

Volumn 36, Issue 1, 2014, Pages 114-136

  Munsell, Mark F ^a   Sprague, Brian L ^a   Berry, Donald A ^a   Chisholm, Gary ^a   Trentham Dietz, Amy ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

body mass index; breast neoplasms; estrogen receptors; meta analysis as topic; postmenopausal hormone replacement therapy; progesterone receptors

Indexed keywords

ESTROGEN; GESTAGEN; HORMONE RECEPTOR;

ARTICLE; BIBLIOGRAPHIC DATABASE; BODY MASS; BREAST CANCER; CANCER RISK; CONFIDENCE INTERVAL; EPIDEMIOLOGICAL DATA; ESTROGEN THERAPY; HORMONE SUBSTITUTION; HUMAN; META ANALYSIS; OBESITY; POSTMENOPAUSE; PREMENOPAUSE; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; SYSTEMATIC REVIEW;

BODY MASS INDEX; BREAST NEOPLASMS; ESTROGEN RECEPTORS; META-ANALYSIS AS TOPIC; POSTMENOPAUSAL HORMONE REPLACEMENT THERAPY; PROGESTERONE RECEPTORS;

AFRICAN CONTINENTAL ANCESTRY GROUP; BODY MASS INDEX; BREAST NEOPLASMS; CAUSALITY; COMORBIDITY; CONFIDENCE INTERVALS; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HISPANIC AMERICANS; HUMANS; OBESITY; POSTMENOPAUSE; PROGESTINS; RECEPTORS, ESTROGEN; RISK FACTORS;

EID: 84891528358     PISSN: 0193936X     EISSN: 14786729     Source Type: Journal    
DOI: 10.1093/epirev/mxt010     Document Type: Article

References (159)

1. Wang Y, Beydoun MA the obesity epidemic in the United States-gender, age, socioeconomic, racial/ethnic, and geographic characteristics: a systematic review and meta-regression analysis. Epidemiol Rev. 2007;29(1):6-28.
2. State-specific prevalence of obesity among adults-United States, 2005. MMWR Morb Mortal Wkly Rep. 2006;55(36): 985-988.
3. Wang YC, McPherson K, Marsh T, et al. Health and economic burden of the projected obesity trends in the USA and the UK. Lancet. 2011;378(9793):815-825.
4. Finkelstein EA, Trogdon JG, Cohen JW, et al. Annual medical spending attributable to obesity: payer-and service-specific estimates. Health Aff (Millwood). 2009;28(5): w822-w831.
5. World Cancer Research Fund/American Institute for Cancer Research. Food, Nutrition, Physical Activity, and the Prevention of Cancer: A Global Perspective. Washington, DC: American Institute for Cancer Research; 2007.
6. Suzuki R, Orsini N, Saji S, et al. Body weight and incidence of breast cancer defined by estrogen and progesterone receptor status-a meta-analysis. Int J Cancer. 2009;124(3): 698-712.
7. Renehan AG, Tyson M, Egger M, et al. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008;371(9612): 569-578.
8. Vrieling A, Buck K, Kaaks R, et al. Adult weight gain in relation to breast cancer risk by estrogen and progesterone receptor status: a meta-analysis. Breast Cancer Res Treat. 2010;123(3):641-649.
9. Althuis MD, Fergenbaum JH, Garcia-Closas M, et al. Etiology of hormone receptor-defined breast cancer: a systematic review of the literature. Cancer Epidemiol Biomarkers Prev. 2004;13(10):1558-1568.
10. Phipps AI, Malone KE, Porter PL, et al. Body size and risk of luminal, HER2-overexpressing, and triple-negative breast cancer in postmenopausal women. Cancer Epidemiol Biomarkers Prev. 2008;17(8):2078-2086.
11. Phipps AI, Chlebowski RT, Prentice R, et al. Body size, physical activity, and risk of triple-negative and estrogen receptor-positive breast cancer. Cancer Epidemiol Biomarkers Prev. 2011;20(3):454-463.
12. Huang Z, Hankinson SE, Colditz GA, et al. Dual effects of weight and weight gain on breast cancer risk. JAMA. 1997; 278(17):1407-1411.
13. Trentham-Dietz A, Newcomb PA, Egan KM, et al. Weight change and risk of postmenopausal breast cancer (United States). Cancer Causes Control. 2000;11(6):533-542.
14. Franceschi S, Favero A, La Vecchia C, et al. Body size indices and breast cancer risk before and after menopause. Int J Cancer. 1996;67(2):181-186.
15. Magnusson C, Baron J, Persson I, et al. Body size in different periods of life and breast cancer risk in post-menopausal women. Int J Cancer. 1998;76(1):29-34.
16. Feigelson HS, Jonas CR, Teras LR, et al. Weight gain, body mass index, hormone replacement therapy, and postmenopausal breast cancer in a large prospective study. Cancer Epidemiol Biomarkers Prev. 2004;13(2):220-224.
17. Friedenreich CM, Courneya KS, Bryant HE. Case-control study of anthropometric measures and breast cancer risk. Int J Cancer. 2002;99(3):445-452.
18. Lahmann PH, Hoffmann K, Allen N, et al. Body size and breast cancer risk: findings from the European Prospective Investigation into Cancer and Nutrition (EPIC). Int J Cancer. 2004;111(5):762-771.
19. Li CI, Malone KE, Daling JR. Interactions between body mass index and hormone therapy and postmenopausal breast cancer risk (United States). Cancer Causes Control. 2006;17(5): 695-703.
20. Wu AH, Yu MC, Tseng CC, et al. Body size, hormone therapy and risk of breast cancer in Asian-American women. Int J Cancer. 2007;120(4):844-852.
21. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results. From theWomen's Health Initiative randomized controlled trial. JAMA. 2002; 288(3):321-333.
22. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA. 2004;291(14):1701-1712.
23. Obesity: preventing and managing the global epidemic. Report of a WHO consultation.World Health Organ Tech Rep Ser. 2000;894:i-xii, 1-253.
24. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539-1558.
25. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177-188.
26. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50(4): 1088-1101.
27. Sterne JA, Egger M. Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. J Clin Epidemiol. 2001;54(10):1046-1055.
28. Sterne JA, Egger M, Smith GD. Systematic reviews in health care: investigating and dealing with publication and other biases in meta-analysis. BMJ. 2001;323(7304): 101-105.
29. Sterne JA, Gavaghan D, Egger M. Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. J Clin Epidemiol. 2000;53(11):1119-1129.
30. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997; 315(7109):629-634.
31. Newcomb PA, Titus-Ernstoff L, Egan KM, et al. Postmenopausal estrogen and progestin use in relation to breast cancer risk. Cancer Epidemiol Biomarkers Prev. 2002; 11(7):593-600.
32. Saxena T, Lee E, Henderson KD, et al. Menopausal hormone therapy and subsequent risk of specific invasive breast cancer subtypes in the California Teachers Study. Cancer Epidemiol Biomarkers Prev. 2010;19(9):2366-2378.
33. Rosenberg LU, Magnusson C, Lindstrom E, et al. Menopausal hormone therapy and other breast cancer risk factors in relation to the risk of different histological subtypes of breast cancer: a case-control study. Breast Cancer Res. 2006;8(1):R11.
34. Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative randomized trial. JAMA. 2003;289(24):3243-3253.
35. Reeves GK, Pirie K, Beral V, et al. Cancer incidence and mortality in relation to body mass index in the MillionWomen Study: cohort study. BMJ. 2007;335(7630):1134.
36. Yang XR, Chang-Claude J, Goode EL, et al. Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst. 2011;103(3):250-263.
37. Pierobon M, Frankenfeld CL. Obesity as a risk factor for triple-negative breast cancers: a systematic review and meta-analysis. Breast Cancer Res Treat. 2013;137(1): 307-314.
38. Eliassen AH, Colditz GA, Rosner B, et al. Adult weight change and risk of postmenopausal breast cancer. JAMA. 2006;296(2):193-201.
39. London SJ, Colditz GA, Stampfer MJ, et al. Prospective study of relative weight, height, and risk of breast cancer. JAMA. 1989;262(20):2853-2858.
40. Harvie M, Howell A, Vierkant RA, et al. Association of gain and loss of weight before and after menopause with risk of postmenopausal breast cancer in the Iowa Women's Health Study. Cancer Epidemiol Biomarkers Prev. 2005;14(3): 656-661.
41. Macinnis RJ, English DR, Gertig DM, et al. Body size and composition and risk of postmenopausal breast cancer. Cancer Epidemiol Biomarkers Prev. 2004;13(12): 2117-2125.
42. Harvie M, Hooper L, Howell AH. Central obesity and breast cancer risk: a systematic review. Obes Rev. 2003;4(3): 157-173.
43. Schapira DV, Kumar NB, Lyman GH, et al. Abdominal obesity and breast cancer risk. Ann Intern Med. 1990;112(3): 182-186.
44. Connolly BS, Barnett C, Vogt KN, et al. A meta-analysis of published literature on waist-to-hip ratio and risk of breast cancer. Nutr Cancer. 2002;44(2):127-138.
45. Mannisto S, Pietinen P, Pyy M, et al. Body-size indicators and risk of breast cancer according to menopause and estrogen-receptor status. Int J Cancer. 1996;68(1):8-13.
46. Huang Z,Willett WC, Colditz GA, et al.Waist circumference, waist:hip ratio, and risk of breast cancer in the Nurses' Health Study. Am J Epidemiol. 1999;150(12):1316-1324.
47. Sexton KR, Franzini L, Day RS, et al. A review of body size and breast cancer risk in Hispanic and African American women. Cancer. 2011;117(23):5271- 5281.
48. Gilliland FD, Hunt WC, Baumgartner KB, et al. Reproductive risk factors for breast cancer in Hispanic and non-Hispanic white women: the New Mexico Women's Health Study. Am J Epidemiol. 1998;148(7):683-692.
49. Wenten M, Gilliland FD, Baumgartner K, et al. Associations of weight, weight change, and body mass with breast cancer risk in Hispanic and non-Hispanic white women. Ann Epidemiol. 2002;12(6):435-444.
50. Slattery ML, Sweeney C, Edwards S, et al. Body size, weight change, fat distribution and breast cancer risk in Hispanic and non-Hispanic white women. Breast Cancer Res Treat. 2007; 102(1):85-101.
51. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet. 1997;350(9084):1047-1059.
52. Hulley S, Furberg C, Barrett-Connor E, et al. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA. 2002;288(1):58-66.
53. Buist DS, Newton KM, Miglioretti DL, et al. Hormone therapy prescribing patterns in the United States. Obstet Gynecol. 2004;104(5 Pt 1):1042-1050.
54. Clarke CA, Glaser SA, Uratsu CS, et al. Recent declines in hormone therapy utilization and breast cancer incidence: clinical and population-based evidence. J Clin Oncol. 2006; 24(33):49-50.
55. Haas JS, Kaplan CP, Gerstenberger EP, et al. Changes in the use of postmenopausal hormone therapy after the publication of clinical trial results. Ann Intern Med. 2004;140(3):184-188.
56. Kerlikowske K, Miglioretti DL, Buist DS, et al. Declines in invasive breast cancer and use of postmenopausal hormone therapy in a screening mammography population. J Natl Cancer Inst. 2007;99(17):1335-1339.
57. Hersh AL, Stefanick ML, Stafford RS. National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA. 2004;291(1):47-53.
58. Ravdin PM, Cronin KA, Howlader N, et al the decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med. 2007;356(16):1670-1674.
59. Chlebowski RT, Anderson GL, Gass M, et al. Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA. 2010;304(15):1684-1692.
60. Sprague BL, Trentham-Dietz A, Cronin KA. A sustained decline in postmenopausal hormone use: results from the National Health and Nutrition Examination Survey, 1999-2010. Obstet Gynecol. 2012;120(3):595-603.
61. Nelson HD,Walker M, Zakher B, et al. Menopausal hormone therapy for the primary prevention of chronic conditions: a systematic review to update the U.S. Preventive Services Task Force recommendations. Ann Intern Med. 2012;157(2): 104-113.
62. Morimoto LM, White E, Chen Z, et al. Obesity, body size, and risk of postmenopausal breast cancer: the Women's Health Initiative (United States). Cancer Causes Control. 2002;13(8): 741-751.
63. van den Brandt PA, Spiegelman D, Yaun SS, et al. Pooled analysis of prospective cohort studies on height, weight, and breast cancer risk. Am J Epidemiol. 2000;152(6):514-527.
64. Ursin G, Tseng CC, Paganini-Hill A, et al. Does menopausal hormone replacement therapy interact with known factors to increase risk of breast cancer? J Clin Oncol. 2002;20(3): 699-706.
65. Rosenberg L, Palmer JR, Wise LA, et al. A prospective study of female hormone use and breast cancer among black women. Arch Intern Med. 2006;166(7):760-765.
66. Brinton LA, Richesson D, Leitzmann MF, et al. Menopausal hormone therapy and breast cancer risk in the NIH-AARP Diet and Health Study Cohort. Cancer Epidemiol Biomarkers Prev. 2008;17(11):3150-3160.
67. Gertig DM, Fletcher AS, English DR, et al. Hormone therapy and breast cancer: what factors modify the association? Menopause. 2006;13(2):178-184.
68. Harris RE, Namboodiri KK, Wynder EL. Breast cancer risk: effects of estrogen replacement therapy and body mass. J Natl Cancer Inst. 1992;84(20):1575-1582.
69. Shantakumar S, Terry MB, Paykin A, et al. Age and menopausal effects of hormonal birth control and hormone replacement therapy in relation to breast cancer risk. Am J Epidemiol. 2007;165(10):1187-1198.
70. Vacek PM, Geller BM. A prospective study of breast cancer risk using routine mammographic breast density measurements. Cancer Epidemiol Biomarkers Prev. 2004; 13(5):715-722.
71. Anderson GL, Chlebowski RT, Aragaki AK, et al. Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial. Lancet Oncol. 2012;13(5):476-486.
72. Davis H, Gergen PJ the weights and heights of Mexican-American adolescents: the accuracy of self-reports. Am J Public Health. 1994;84(3):459-462.
73. Kushi LH, Kaye SA, Folsom AR, et al. Accuracy and reliability of self-measurement of body girths. Am J Epidemiol. 1988;128(4):740-748.
74. Must A, Willett WC, Dietz WH. Remote recall of childhood height, weight, and body build by elderly subjects. Am J Epidemiol. 1993;138(1):56-64.
75. Rimm EB, Stampfer MJ, Colditz GA, et al. Validity of self-reported waist and hip circumferences in men and women. Epidemiology. 1990;1(6):466-473.
76. Stewart AL the reliability and validity of self-reported weight and height. J Chronic Dis. 1982;35(4):295-309.
77. Stunkard AJ, Albaum JM the accuracy of self-reported weights. Am J Clin Nutr. 1981;34(8):1593-1599.
78. Goodman MT, Nomura AM, Wilkens LR, et al. Agreement between interview information and physician records on history of menopausal estrogen use. Am J Epidemiol. 1990; 131(5):815-825.
79. Greendale GA, James MK, Espeland MA, et al. Can we measure prior postmenopausal estrogen/progestin use? The Postmenopausal Estrogen/Progestin Interventions Trial the PEPI investigators. Am J Epidemiol. 1997;146(9): 763-770.
80. Jain MG, Rohan TE, Howe GR. Agreement of self-reported use of menopausal hormone replacement therapy with physician reports. Epidemiology. 1999;10(3):260-263.
81. Jannausch ML, Sowers MR. Consistency of perimenopausal estrogen use reporting by women in a population-based prospective study. Maturitas. 1992;14(3):161-169.
82. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer. 2004;4(8):579-591.
83. Key T, Appleby P, Barnes I, et al. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst. 2002;94(8): 606-616.
84. Eliassen AH, Spiegelman D, Xu X, et al. Urinary estrogens and estrogen metabolites and subsequent risk of breast cancer among premenopausal women. Cancer Res. 2012;72(3): 696-706.
85. Potischman N, Swanson CA, Siiteri P, et al. Reversal of relation between body mass and endogenous estrogen concentrations with menopausal status. J Natl Cancer Inst. 1996;88(11):756-758.
86. Rich-Edwards JW,GoldmanMB,WillettWC, et al.Adolescent body mass index and infertility caused by ovulatory disorder. Am J Obstet Gynecol. 1994;171(1):171-177.
87. Siiteri PK. Adipose tissue as a source of hormones. Am J Clin Nutr. 1987;45(1 suppl):277-282.
88. Key TJ, Appleby PN, Reeves GK, et al. Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. J Natl Cancer Inst. 2003;95(16):1218-1226.
89. Renehan AG, Frystyk J, Flyvbjerg A. Obesity and cancer risk: the role of the insulin-IGF axis. Trends Endocrinol Metab. 2006;17(8):328-336.
90. Rose DP, Komninou D, Stephenson GD. Obesity, adipocytokines, and insulin resistance in breast cancer. Obes Rev. 2004;5(3):153-165.
91. Interagency Breast Cancer and the Environment Research Coordinating Committee. Breast cancer and the environment: prioritizing prevention. Bethesda, MD: National Institutes of Health; 2013. (http://www.niehs.nih.gov/about/ assets/docs/ibcercc-full-508.pdf). (Accessed August 21, 2013).
92. Ahn J, Schatzkin A, Lacey JV Jr, et al. Adiposity, adult weight change, and postmenopausal breast cancer risk. Arch Intern Med. 2007;167(19):2091-2102.
93. Barlow WE, White E, Ballard-Barbash R, et al. Prospective breast cancer risk prediction model for women undergoing screening mammography. J Natl Cancer Inst. 2006;98(17): 1204-1214.
94. Barnes BB, Steindorf K, Hein R, et al. Population attributable risk of invasive postmenopausal breast cancer and breast cancer subtypes for modifiable and nonmodifiable risk factors. Cancer Epidemiol. 2011;35(4): 345-352.
95. Berstad P, Coates RJ, Bernstein L, et al. A case-control study of body mass index and breast cancer risk in white and African-American women. Cancer Epidemiol Biomarkers Prev. 2010;19(6):1532-1544.
96. Boyd NF, Martin LJ, Sun L, et al. Body size, mammographic density, and breast cancer risk. Cancer Epidemiol Biomarkers Prev. 2006;15(11):2086-2092.
97. Cerne JZ, Ferk P, Leskosek B, et al. Hormone replacement therapy and some risk factors for breast cancer among Slovenian postmenopausal women. Climacteric. 2011;14(4): 458-463.
98. Chang SC, Ziegler RG, Dunn B, et al. Association of energy intake and energy balance with postmenopausal breast cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Cancer Epidemiol Biomarkers Prev. 2006; 15(2):334-341.
99. Chlebowski RT, Anderson GL, Lane DS, et al. Predicting risk of breast cancer in postmenopausal women by hormone receptor status. J Natl Cancer Inst. 2007;99(22): 1695-1705.
100. Cotterchio M, Kreiger N, Theis B, et al. Hormonal factors and the risk of breast cancer according to estrogen-and progesterone-receptor subgroup. Cancer Epidemiol Biomarkers Prev. 2003;12(10):1053-1060.
101. Cust AE, Stocks T, Lukanova A, et al the influence of overweight and insulin resistance on breast cancer risk and tumour stage at diagnosis: a prospective study. Breast Cancer Res Treat. 2009;113(3):567-576.
102. Eng SM, Gammon MD, Terry MB, et al. Body size changes in relation to postmenopausal breast cancer among women on Long Island, New York. Am J Epidemiol. 2005;162(3): 229-237.
103. Gaudet MM, Falk RT, Gierach GL, et al. Do adipokines underlie the association between known risk factors and breast cancer among a cohort of United States women? Cancer Epidemiol. 2010;34(5):580-586.
104. Hall IJ, Newman B, Millikan RC, et al. Body size and breast cancer risk in black women and white women: the Carolina Breast Cancer Study. Am J Epidemiol. 2000;151(8):754-764.
105. Harlid S, Butt S, Ivarsson MI, et al. Interactive effect of genetic susceptibility with height, body mass index, and hormone replacement therapy on the risk of breast cancer. BMC Womens Health. 2012;12(17).
106. Hines LM, Risendal B, Slattery ML, et al. Comparative analysis of breast cancer risk factors among Hispanic and non-Hispanic white women. Cancer. 2010;116(13): 3215-3223.
107. Hislop TG, Coldman AJ, Elwood JM, et al. Relationship between risk factors for breast cancer and hormonal status. Int J Epidemiol. 1986;15(4):469-476.
108. Huang WY, Newman B, Millikan RC, et al. Hormone-related factors and risk of breast cancer in relation to estrogen receptor and progesterone receptor status. Am J Epidemiol. 2000; 151(7):703-714.
109. John EM, Horn-Ross PL, Koo J. Lifetime physical activity and breast cancer risk in a multiethnic population: the San Francisco Bay area breast cancer study. Cancer Epidemiol Biomarkers Prev. 2003;12(11 Pt 1):1143-1152.
110. John EM, Sangaramoorthy M, Phipps AI, et al. Adult body size, hormone receptor status, and premenopausal breast cancer risk in a multiethnic population: the San Francisco Bay area breast cancer study. Am J Epidemiol. 2011;173(2): 201-216.
111. Jumaan AO, Holmberg L, Zack M, et al. Beta-carotene intake and risk of postmenopausal breast cancer. Epidemiology. 1999;10(1):49-53.
112. Krebs EE, Taylor BC, Cauley JA, et al. Measures of adiposity and risk of breast cancer in older postmenopausal women. J Am Geriatr Soc. 2006;54(1):63-69.
113. Li CI, Stanford JL, Daling JR. Anthropometric variables in relation to risk of breast cancer in middle-aged women. Int J Epidemiol. 2000;29(2):208-213.
114. Ma H, Bernstein L, Ross RK, et al. Hormone-related risk factors for breast cancer in women under age 50 years by estrogen and progesterone receptor status: results from a case-control and a case-case comparison. Breast Cancer Res. 2006;8(4):R39.
115. Meier CR, Schmitz S, Jick H. Association between acetaminophen or nonsteroidal antiinflammatory drugs and risk of developing ovarian, breast, or colon cancer. Pharmacotherapy. 2002;22(3):303-309.
116. Michels KB, Terry KL,Willett WC. Longitudinal study on the role of body size in premenopausal breast cancer. Arch Intern Med. 2006;166(21):2395-2402.
117. Modugno F, Kip KE, Cochrane B, et al. Obesity, hormone therapy, estrogen metabolism and risk of postmenopausal breast cancer. Int J Cancer. 2006;118(5):1292-1301.
118. Nemesure B, Wu SY, Hennis A, et al. Body size and breast cancer in a black population-the Barbados National Cancer Study. Cancer Causes Control. 2009;20(3):387-394.
119. Obi N, Chang-Claude J, Berger J, et al the use of herbal preparations to alleviate climacteric disorders and risk of postmenopausal breast cancer in a German case-control study. Cancer Epidemiol Biomarkers Prev. 2009;18(8):2207-2213.
120. Palmer JR, Adams-Campbell LL, Boggs DA, et al. A prospective study of body size and breast cancer in black women. Cancer Epidemiol Biomarkers Prev. 2007;16(9): 1795-1802.
121. Pan SY, Johnson KC, Ugnat AM, et al. Association of obesity and cancer risk in Canada. Am J Epidemiol. 2004;159(3): 259-268.
122. Peacock SL, White E, Daling JR, et al. Relation between obesity and breast cancer in young women. Am J Epidemiol. 1999;149(4):339-346.
123. Rinaldi S, Key TJ, Peeters PH, et al. Anthropometric measures, endogenous sex steroids and breast cancer risk in postmenopausal women: a study within the EPIC cohort. Int J Cancer. 2006;118(11):2832-2839.
124. Rosenberg LU, Einarsdottir K, Friman EI, et al. Risk factors for hormone receptor-defined breast cancer in postmenopausal women. Cancer Epidemiol Biomarkers Prev. 2006;15(12): 2482-2488.
125. SarkissyanM,Wu Y, Vadgama JV. Obesity is associated with breast cancer in African-American women but not Hispanic women in South Los Angeles. Cancer. 2011;117(16): 3814-3823.
126. Silvera SA, Jain M, Howe GR, et al. Energy balance and breast cancer risk: a prospective cohort study. Breast Cancer Res Treat. 2006;97(1):97-106.
127. Suzuki R, Rylander-Rudqvist T, YeW, et al. Body weight and postmenopausal breast cancer risk defined by estrogen and progesterone receptor status among Swedish women: a prospective cohort study. Int J Cancer. 2006;119(7): 1683-1689.
128. Swanson CA, Brinton LA, Taylor PR, et al. Body size and breast cancer risk assessed in women participating in the Breast Cancer Detection Demonstration Project. Am J Epidemiol. 1989;130(6):1133-1141.
129. Swanson CA, Coates RJ, Schoenberg JB, et al. Body size and breast cancer risk among women under age 45 years. Am J Epidemiol. 1996;143(7):698-706.
130. Sweeney C, Blair CK, Anderson KE, et al. Risk factors for breast cancer in elderly women. Am J Epidemiol. 2004;160(9): 868-875.
131. Toniolo P, Riboli E, Shore RE, et al. Consumption of meat, animal products, protein, and fat and risk of breast cancer: a prospective cohort study in New York. Epidemiology. 1994; 5(4):391-397.
132. Tornberg SA, Carstensen JM. Relationship between Quetelet's index and cancer of breast and female genital tract in 47,000 women followed for 25 years. Br J Cancer. 1994; 69(2):358-361.
133. Trentham-Dietz A, Newcomb PA, Storer BE, et al. Body size and risk of breast cancer. Am J Epidemiol. 1997;145(11): 1011-1019.
134. van den Brandt PA, Dirx MJ, Ronckers CM, et al. Height, weight, weight change, and postmenopausal breast cancer risk: the Netherlands Cohort Study. Cancer Causes Control. 1997;8(1):39-47.
135. Vatten LJ, Kvinnsland S. Prospective study of height, body mass index and risk of breast cancer. Acta Oncol. 1992;31(2): 195-200.
136. Weiderpass E, Braaten T, Magnusson C, et al. A prospective study of body size in different periods of life and risk of premenopausal breast cancer. Cancer Epidemiol Biomarkers Prev. 2004;13(7):1121-1127.
137. White KK, Park SY, Kolonel LN, et al. Body size and breast cancer risk: the Multiethnic Cohort. Int J Cancer. 2012; 131(5):E705-E716.
138. Zhu K, Caulfield J, Hunter S, et al. Body mass index and breast cancer risk in African American women. Ann Epidemiol. 2005;15(2):123-128.
139. Bakken K, Fournier A, Lund E, et al. Menopausal hormone therapy and breast cancer risk: impact of different treatments the European Prospective Investigation into Cancer and Nutrition. Int J Cancer. 2011;128(1):144-156.
140. Beral V, Reeves G, Bull D, et al. Breast cancer risk in relation to the interval between menopause and starting hormone therapy. J Natl Cancer Inst. 2011;103(4):296-305.
141. Chen CL,Weiss NS, Newcomb P, et al. Hormone replacement therapy in relation to breast cancer. JAMA. 2002;287(6): 734-741.
142. Chen WY, Hankinson SE, Schnitt SJ, et al. Association of hormone replacement therapy to estrogen and progesterone receptor status in invasive breast carcinoma. Cancer. 2004; 101(7):1490-1500.
143. Ewertz M, Mellemkjaer L, Poulsen AH, et al. Hormone use for menopausal symptoms and risk of breast cancer. A Danish cohort study. Br J Cancer. 2005;92(7): 1293-1297.
144. Fournier A, Berrino F, Riboli E, et al. Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int J Cancer. 2005;114(3): 448-454.
145. Fournier A, Fabre A, Mesrine S, et al. Use of different postmenopausal hormone therapies and risk of histology-and hormone receptor-defined invasive breast cancer. J Clin Oncol. 2008;26(8):1260-1268.
146. Kotsopoulos J, Tworoger SS, De Vivo I, et al. +331G/A variant in the progesterone receptor gene, postmenopausal hormone use and risk of breast cancer. Int J Cancer. 2009; 125(7):1685-1691.
147. Lee S, Kolonel L, Wilkens L, et al. Postmenopausal hormone therapy and breast cancer risk: the Multiethnic Cohort. Int J Cancer. 2006;118(5):1285-1291.
148. Li CI, Weiss NS, Stanford JL, et al. Hormone replacement therapy in relation to risk of lobular and ductal breast carcinoma in middle-aged women. Cancer. 2000;88(11): 2570-2577.
149. Li CI, Malone KE, Porter PL, et al. Relationship between menopausal hormone therapy and risk of ductal, lobular, and ductal-lobular breast carcinomas. Cancer Epidemiol Biomarkers Prev. 2008;17(1):43-50.
150. Lyytinen HK, Dyba T, Ylikorkala O, et al. A case-control study on hormone therapy as a risk factor for breast cancer in Finland: intrauterine system carries a risk as well. Int J Cancer. 2010;126(2):483-489.
151. Newcomb PA, Longnecker MP, Storer BE, et al. Long-term hormone replacement therapy and risk of breast cancer in postmenopausal women. Am J Epidemiol. 1995;142(8): 788-795.
152. Opatrny L, Dell'Aniello S, Assouline S, et al. Hormone replacement therapy use and variations in the risk of breast cancer. BJOG. 2008;115(2):169-175; discussion 175.
153. Persson I, Weiderpass E, Bergkvist L, et al. Risks of breast and endometrial cancer after estrogen and estrogen-progestin replacement. Cancer Causes Control. 1999;10(4):253-260.
154. Reding KW, Chen C, Lowe K, et al. Estrogen-related genes and their contribution to racial differences in breast cancer risk. Cancer Causes Control. 2012;23(5):671-681.
155. Schairer C, Byrne C, Keyl PM, et al. Menopausal estrogen and estrogen-progestin replacement therapy and risk of breast cancer (United States). Cancer Causes Control. 1994;5(6):491-500.
156. Sprague BL, Trentham-Dietz A, Egan KM, et al. Proportion of invasive breast cancer attributable to risk factors modifiable after menopause. Am J Epidemiol. 2008;168(4):404-411.
157. Stahlberg C, Pedersen AT, Andersen ZJ, et al. Breast cancer with different prognostic characteristics developing in Danish women using hormone replacement therapy. Br J Cancer. 2004;91(4):644-650.
158. Weiss LK, Burkman RT, Cushing-Haugen KL, et al. Hormone replacement therapy regimens and breast cancer risk(1). Obstet Gynecol. 2002;100(6):1148- 1158.
159. Yang CP, Daling JR, Band PR, et al. Noncontraceptive hormone use and risk of breast cancer. Cancer Causes Control. 1992;3(5):475-479.